Matitiahu Berkovitch

Matitiahu Berkovitch

Auto-generated profile, based on publicly available information

Matitiahu Berkovitch

Clinical Pharmacology and Toxicology Unit, Shamir (Assaf Harofeh) Medical Center, Zerifin, Affiliated to the Gray Faculty of Medical & Health Sciences, Tel-Aviv University, Israel

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2007 in Birth Defects Research Part A: Clinical and Molecular Teratology
Verified
Journal Article
Closed access
PDF file
LGLee Hilary Goldstein
Lee Hilary Goldstein
GDGalit Dolinsky
Galit Dolinsky
RGRevital Greenberg
Revital Greenberg
CSChristof Schaefer
Christof Schaefer
RCRaanan Cohen‐Kerem
Raanan Cohen‐Kerem
MBMatitiahu Berkovitch
Matitiahu Berkovitch

1 January 2003 in Drug Safety
Verified
Journal Article
Closed access
PDF file
BBBenjamin Bar-Oz
Benjamin Bar-Oz
MBMordechai Bulkowstein
Mordechai Bulkowstein
LBLilach Benyamini
Lilach Benyamini
RGRevital Greenberg
Revital Greenberg
ISIngrid Soriano
Ingrid Soriano
MBMatitiahu Berkovitch
Matitiahu Berkovitch

10 March 2003 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
EKEran Kozer
Eran Kozer
SESandra Evans
Sandra Evans
JBJoseph Barr
Joseph Barr
RGRevital Greenberg
Revital Greenberg
ISIngrid Soriano
Ingrid Soriano
MBMatitiahu Berkovitch
Matitiahu Berkovitch

4 June 2004 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
MBMatitiahu Berkovitch
Matitiahu Berkovitch
ODOrna Diav‐Citrin
Orna Diav‐Citrin
RGRevital Greenberg
Revital Greenberg
MCMichal Cohen
Michal Cohen
MBMordechai Bulkowstein
Mordechai Bulkowstein
Asher OrnoyAsher Ornoy
Asher Ornoy
Aims: The number of published studies on the use of amoxycillin/clavulanic acid during pregnancy is small and so is the number of pregnancies investigated in those studies. In this study we wished to investigate prospectively the safety of intrauterine exposure to amoxycillin/clavulanic acid in a relatively large cohort of women.Methods: Women treated (n = 191) with amoxycillin/clavulanic acid during the first trimester of pregnancy were recruited from two teratogen information centres in Israel. Exposed women were matched for age, smoking habits and alcohol consumption with 191 controls exposed to amoxycillin only for similar medical indications.Results: Maternal age, birth weight, gestational age at delivery, rates of live births and abortions were comparable between the two groups. Rates of major malformations in the amoxycillin/clavulanic acid group (3/158, 1.9%) did not differ significantly from controls (5/163, 3%) (P = 0.49, relative risk = 0.62, 95% confidence interval 0.15, 2.55), and were within the expected baseline risk for the general population.Conclusion: These data suggest that exposure to amoxycillin/clavulanic acid during pregnancy is unlikely to be associated with an increased risk of malformations.

17 July 2017 in Birth Defects Research
Verified
Journal Article
Closed access
PDF file
NKNirit Kronenfeld
Nirit Kronenfeld
MBMaya Berlin
Maya Berlin
DSDotan Shaniv
Dotan Shaniv
MBMatitiahu Berkovitch
Matitiahu Berkovitch

1 June 2015 in Pediatric Neurology
Verified
Journal Article
Closed access
RSRevital Sheinberg
Revital Sheinberg
EHEli Heyman
Eli Heyman
ZDZahi Dagan
Zahi Dagan
IYIlan Youngster
Ilan Youngster
EKElkana Kohn
Elkana Kohn
MBMatitiahu Berkovitch
Matitiahu Berkovitch